Prostate cancer is the most commonly diagnosed cancer in the United States. Prostate cells contain vitamin D receptors as well as enzymes necessary for vitamin D metabolism. Vitamin D metabolites have an antiproliferative and a pro-differentiating effect on prostate cancer cell lines in vitro and in vivo. As a result, there has been an emerging interest in the potential role of vitamin D in the etiology of prostate cancer. This review summarizes all available epidemiological literature on the association between dietary vitamin D, circulating levels of vitamin D and sunlight exposure in relation to prostate cancer risk. To place these studies in context, we also provide some background information on vitamin D, such as its dietary sources, metabolism, optimal levels, hypovitaminosis and relationship with the prostate.
Introduction
Prostate cancer is the sixth most common cancer in the world, the third most common cancer in men worldwide and the most common cancer in men in Europe and North America, [1] [2] [3] [4] [5] with a new case diagnosed every 3 min. 6 The increasing incidence of prostate cancer is because of its strong association with age in combination with the rising average age of American men, improvements in detection techniques and programs for the early detection of prostate cancer. [7] [8] [9] Each year in the United States, approximately 220 000 new cases of prostate cancer are diagnosed, and 30 000 men die of the disease. 9 The mean age of patients with this disorder is 72-74 years, and about 85% of patients are diagnosed after 65 years of age. 5 Prostate cancer is the second leading cause of cancer death among US men after lung cancer. 6, 10 Similar to most other cancer types, prostate cancer epidemiology is not fully known. The available information does not completely explain the causation and pathogenesis of the disease. Research is in progress to establish the missing links in the association of etiologic factors, such as dietary habits, [11] [12] [13] with prostate carcinogenesis. A high intake of red meat is one such dietary habit that has been linked to prostate cancer. [13] [14] [15] The incidence varies among different racial/ethnic populations and is the lowest among Asians (Japanese, 39/ 100 000; Chinese, 28/100 000) 16 and vegetarians. 5, 17 The highest incidence of prostate cancer is seen in North America and Scandinavia, especially in African-American men in the United States (137 per 100 000 per year). 5 In Uganda 18 and Nigeria, 19, 20 prostate cancer is very common, and in Nigeria it is the most common cancer in men. Another factor that influences the occurrence of the disease is obesity. 21 Both body mass index and lean body mass were positively associated with the risk of prostate cancer and were more strongly related to mortality than to incidence. Other factors that influence the occurrence of the disease are dietary habits (diet that includes a high intake of fat, meat and dairy products), 22, 23 pattern of sexual behavior, alcohol consumption, 24 exposure to ultraviolet radiation, 22, [25] [26] [27] [28] occupational exposure 29 and familial genetic inheritance. 5, [30] [31] [32] [33] [34] [35] Finally, factors such as smoking, 36 vasectomy 37 and physical activity 38 have been investigated in several studies, but the general consensus is that they do not affect risk of prostate cancer.
It is known that prostate cells contain vitamin D receptors (VDRs) as well as enzymes necessary for vitamin D metabolism. In vitro studies show the anticarcinogenic properties of vitamin D. Vitamin D metabolites have an antiproliferative and a pro-differentiating effect on prostate cancer cell lines in vitro and in vivo. [39] [40] [41] [42] [43] [44] The physiological levels of 1,25-dihydroxyvitamin D (1,25(OH)2D 3 ) reveal impressive antimetastatic effects on prostate cancer cells in vivo. 45 In 1993, Skowronski et al. 46 discovered that all three of the prostate cancer cell lines they studied possessed a VDR and that the active form of vitamin D, calcitriol, 'dramatically inhibited' the growth of two of the three cell lines. From the abovementioned studies, it was suggested that the expression of functional VDR is necessary, but not sufficient, for maximal growth inhibition by 1,25(OH)2D 3 . 47 The finding that 1,25(OH)2D 3 shows antiproliferative, pro-differentiation and antimetastatic effects could open new avenues to the development and targeting of chemopreventive interventions. However, 1,25(OH)2D 3 may not be a suitable agent for use as a chemopreventive agent because of the risk of hypercalcemia. 48 These findings, combined with the epidemiological evidence on the association between low prostate cancer risk and high levels of vitamin D, warrant additional avenues of investigation in this field.
Given the emerging interest in the potential role of vitamin D in the etiology of prostate cancer, we review here the current epidemiological literature on vitamin D in relation to prostate cancer risk. We start by providing some background information on vitamin D, such as its dietary sources, metabolism, optimal levels, hypovitaminosis and relationship with the prostate.
Basic facts about vitamin D
Vitamin D is a fat-soluble steroid prohormone well known for its role in maintaining bone health. 49 Vitamin D is available in small amounts in foods such as fish, eggs and fortified dairy products. In addition, many multivitamins and supplements containing vitamin D are available. 50 Vitamin D 3 is also produced in skin when exposed to sunlight, specifically ultraviolet B radiation. 7-Dehydrocholestrol is converted into vitamin D 3 , when skin is exposed to sun. 51 66 and a lower estimated glomerular filtration rate. 67 Mean vitamin D levels vary by race/ethnicity, 65 with the highest levels in nonHispanic whites, intermediate levels in Mexican Americans and the lowest levels in non-Hispanic blacks. Vitamin D levels vary by region and are greater in summer than in winter months. 68, 69 Higher skin melanin levels increase the risk of vitamin D deficiency. African Americans are more prone to be deficient because of higher skin melanin levels. 70 Vitamin D inadequacy constitutes a largely unrecognized epidemic in many populations worldwide [71] [72] [73] It has been reported in healthy children, 74 adolescents 75 and adults.
76,77
Vitamin D and prostate health
Normal and malignant prostate cells contain VDRs, [78] [79] [80] which mediate the antiproliferative action of 1,25(OH)2D. 1,25(OH)2D, the biologically active form of vitamin D, binds to nuclear VDRs in the epithelial cells of the prostate. It has a specific affinity for specific DNA sequences, namely vitamin D response elements. 81 1,25(OH)2D is capable of acting through both nongenomic signaling pathways involving a membraneassociated receptor and genomic pathways involving the nuclear VDR. The binding of vitamin D to these response elements evokes a cascade of genetic events, thus becoming responsible for the formation of proteins. 82 1,25(OH)2D diffuses passively into the cells to bind to the receptor causing a conformational change in the VDR, allowing dimerization with the retinoid Â receptor. Dimerization enables interaction with the vitamin D response element on target genes, initiating transcription. Vitamin D response element is also found on genes related to cellular differentiation and proliferation, including p21, transforming growth factor-b2, fibronectin, urokinase plasminogen activator and b integrin. These gene products interact with and inhibit cyclindependent kinases, preventing uncontrolled progression through the cell cycle. Vitamin D response elements have also been identified as the promoters of insulin-like growth factor-binding protein-3 and insulin receptor genes. 1,25(OH)2D, therefore, plays an important role in the growth and function of the normal prostate, as well as in prostate carcinogenesis. 10 The reason is that most of the actions of vitamin D are mediated through an intracellular receptor in the prostate that has a much higher affinity for 1,25(OH)2D than for other metabolites. In addition to the antiproliferative action of 1,25(OH)2D, it can cause apoptosis, 39 induce differentiation, 83 inhibit telomerase expression, 84 inhibit tumor cell invasiveness 45 and suppress tumor-induced angiogenesis. 85 Epidemiological studies of vitamin D and prostate cancer risk
Search strategy and selection criteria
We conducted MEDLINE searches to identify epidemiological studies on the relationship between vitamin D Table 1 summarizes the epidemiological studies on the association between vitamin D intake and prostate cancer risk. A study found that there is an increased incidence of prostate cancer in migrant Asians as they adopt a Western diet, that is, lacking the large amount of vitamin-D-rich fish oil. 93 In 1992, Hanchette and Schwartz 22 pointed out that men in the United States were 10 times more likely to develop prostate cancer than men in Japan, where men consume higher amounts of vitamin D because of their consumption of fatty fish. Furthermore, traditional Japanese men consume higher quantities of omega-3 fatty acids than their American counterparts. These fats are known to dissociate vitamin D metabolites from their binding protein, thus raising active levels of those metabolites in the blood.
A study found that a high calcium consumption, largely from dairy products, increases the risk of prostate cancer by lowering the levels of circulating 1,25(OH)D. It is the bioactive metabolite of vitamin D that was thought to protect against prostate carcinogenesis, and the conversion of the precursor 25(OH)D to 1,25(OH)2D is inhibited by high calcium intake. However, continuous measures of dietary vitamin D intake were not associated with risk of prostate cancer. 91 The Alpha-Tocopherol Beta-Carotene Cancer Prevention Study investigated the associations between various nutrients hypothesized to influence 1,25(OH)2D (calcium, phosphorus, fructose and animal protein), as well as other aspects of diet, and prostate cancer risk. The study examined six major food groups (dairy, red meat, fish and poultry, vegetables, fruits (including berries) and cereals), the three major macronutrients (fat, protein and carbohydrates), total energy, calcium, phosphorus, vitamin D and fructose. None of the foods or nutrients examined were significantly associated with the risk. 94 Another study assessing the relationship between calcium, phosphorus and vitamin D dietary intake and prostate cancer risk, taking into account the potential confounding effect of several covariates, found no association between selfreported measures of vitamin D intake (obtained retrospectively) and the risk of prostate cancer. 95 Similarly, a prospective study of 3612 men followed from 1982-1984 to 1992 for the first National Health and Nutrition Examination Epidemiologic Follow-up Study was conducted to examine the association of dairy, calcium and vitamin D intake with prostate cancer. Dietary calcium was strongly associated with increased risk (relative risk (RR) ¼ 2.2; 95% confidence interval (CI) ¼ 1.4, 3.5; third compared with first tertile; trend P ¼ 0.001). After adjustment for calcium intake, neither vitamin D nor phosphorus was associated with risk. 96 A multiethnic cohort study (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) examined the association of high intakes of calcium and dairy products with prostate cancer risk among 82 483 men who completed a detailed quantitative food frequency questionnaire. Nutrient and food intakes were divided into quintiles and no association was found between calcium and vitamin D intake and total, advanced or high-grade prostate cancer risk. In analyses of food groups, dairy product and total milk consumption were not associated with prostate cancer risk. However, low-/non-fat milk was related to an increased risk and whole milk to a decreased risk of total prostate cancer. After stratification, these effects were limited to localized or low-grade tumors. 97 Another study examined the available evidence and sources of heterogeneity for studies of dairy products, calcium, and vitamin D intake and the risk of prostate cancer. The study collected data from 45 observational studies using a general variance-based, meta-analytic method employing CIs. Cohort studies showed no evidence of an association between dairy (RR ¼ 1.06; 95% CI ¼ 0.92-1.22) or milk intake (RR ¼ 1.06; 95% CI ¼ 0.91-1.23) and the risk of prostate cancer. This was supported by pooled results of case-control analyses (RR ¼ 1.14; 95% CI ¼ 1.00-1.29), although studies using milk as the exposure of interest were heterogeneous and could not be combined. Dietary intake of vitamin D was not related to prostate cancer risk. 98 The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial study prospectively examined the association of dairy products and calcium intake with prostate cancer risk in 29 509 men, including 1910 cases. A greater intake of dairy products, particularly low-fat dairy products, was weakly associated with increased risk of prostate cancer. Dietary vitamin D was not associated with prostate cancer; however, risk tends to decrease with greater vitamin D from supplemental sources, with a 40% reduction in men who used 4600 IU of supplemental vitamin D compared with men not using vitamin D supplements. 99 Another study analyzed 454 male participants in the Baltimore Longitudinal Study of Aging who were 46-92 years old at the time of completion of a food frequency questionnaire. The adjusted odds ratio (OR) of prostate cancer for the highest tertile compared with that for the lowest tertile of vitamin D was 1.21 (95% CI ¼ 0.64-2.30; P-trend ¼ 0.46). Likewise, no significant trends were found for phosphorus, fructose or animal Vitamin D and prostate cancer risk D Gupta et al protein intake. Dairy products, including milk, were not associated with an increased risk of prostate cancer. 100 Finally, one additional study examined the associations of energy, fat, vitamin D and calcium with risk of prostate cancer in 605 incident cases of prostate cancer and 592 controls. Self-administered food frequency questionnaires were used to assess diet over the 3-to 5-year period before diagnosis or interview date. Total energy was associated with increased risk for both local and regional/distant-stage disease. The adjusted ORs contrasting highest to lowest quintile of energy intake were 2.15 (95% CI ¼ 1.35-3.43) for local and 1.96 (95% CI ¼ 1.08-3.56) for regional/distant disease. Fat was associated with regional/distant disease only. However, there were no associations of vitamin D, total polyunsaturated fatty acids or the highly unsaturated, longchain eicosapentenoic and docosahexaenoic fatty acids with prostate cancer risk. 105 In a yet another study, serum 25(OH)D levels of 622 prostate cancer cases and 1451 matched controls were investigated, and it was found that both low (o19 nmol l À1 ) and high (480 nmol l À1 ) 25(OH)D serum concentrations are associated with a higher prostate cancer risk. 106 A study by Clemens et al. 107 Several studies have been conducted to evaluate this association as shown in Table 3 . One study compared UVB exposure between 210 cases and 155 controls. Childhood sunburn, regular foreign holidays, sunbathing score and low exposure to UVB were associated with the development of prostate cancer. Furthermore, cases with low UVB exposure developed cancer at a younger median age than cases with higher exposure. Thus, it was concluded that UVB had a protective effect against development of prostate cancer. 28 In 1992, Hanchette and Schwartz 22 proposed that sunlight and vitamin D may play a role in prostate cancer. Mortality rates in the United States from prostate cancer showed a negative correlation with UVB exposure. To support their hypothesis, Hanchette and Schwartz analyzed American prostate cancer deaths in relation to sunlight and discovered a 0.0001 negative correlation. That is, they found that men who received more sunlight were less likely to die from prostate cancer. In the same year, Schwartz discovered that death rates from prostate cancer were correlated with death rates from multiple sclerosis, another disease known to be associated with a lack of sunlight. Again, he proposed that lack of vitamin D may be a causative factor in both diseases. 114 Another study conducted to determine the association of sunlight exposure with prostate cancer risk showed that sun exposure and VDR polymorphisms together play an important role in the etiology of prostate cancer. Interview data on lifetime sun exposure and other risk factors were collected for 905 non-Hispanic white men (450 cases and 455 controls). A reduced risk of advanced prostate cancer was associated with high sun exposure determined by reflectometry and high occupational outdoor activity. 26 Yet another study analyzed data from the first National Health and Nutrition Examination Survey to test the hypothesis that residential sunlight exposure reduces the risk of prostate cancer and found that residence in the southern United States at baseline (RR ¼ 0. were associated with significant and substantial reductions in prostate cancer risk. 25 Analysis of data from the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study was conducted to examine associations of prostate cancer risk with earlylife and adult residential sun exposure and adult sun exposures. Solar radiation in the state of birth was used as a measure of sun exposure in early life. Significant inverse associations were found for men born in a region of high solar radiation, with a slightly greater reduction for fatal than for non-fatal prostate cancer. Frequent recreational sun exposure in adulthood was associated In a cohort study, the incidence rates of prostate cancer among skin cancer patients were compared with those in the reference population. Skin cancer patients were at a decreased risk of developing prostate cancer compared with the general population (standardized incidence ratio ( Another study was conducted to assess whether patients with skin cancer have an altered risk of developing other cancers. The study cohort consisted of 416 134 cases of skin cancer and 3 776 501 cases of nonskin cancer as a first cancer extracted from 13 cancer registries. The observed numbers (O) of 46 types of second primary cancer after skin melanoma, basal cell carcinoma or non-basal cell carcinoma, and of skin cancers following non-skin cancers, were compared with the expected numbers (E) derived from the age-, sex-and calendar period-specific cancer incidence rates in each of the cancer registries (O/E ¼ SIR). Rates from cancer registries classified to sunny countries (Australia, Singapore and Spain) and less sunny countries (Canada, Denmark, Finland, Iceland, Norway, Scotland, Slovenia and Sweden) were compared with each other. SIR of all second solid primary cancers (except skin and lip) after skin melanoma were significantly lower for the sunny countries (SIR(S) ¼ 1.03; 95% CI ¼ 0.99-1.08) than that for the less sunny countries (SIR(L) ¼ 1.14; 95% CI ¼ 1.11-1.17). The study concluded that vitamin D production in the skin decreased the risk of several solid cancers (especially stomach, colorectal, liver and gallbladder, pancreas, lung, female breast, prostate, bladder and kidney cancers). 117 Similarly, another study was conducted to investigate whether the incidence of prostate cancer and mortality rates in the United States correlated inversely with UVB radiation levels computed from a mathematical model using forecasted ozone levels, cloud levels and elevation. The authors found an inverse correlation between the UVB levels and prostate cancer incidence (R ¼ À0.42, Po0.01) and mortality rates (R ¼ À0.53, Po0.001) for white men and for incidence (R ¼ À0.40, Po0.05) for black men, but the strength of the correlation depended on the season of UVB irradiance. The annual prostate cancer incidence and mortality rates for white men correlated most strongly with UVB exposure levels in the fall and winter, and incidence rates for black men correlated with UVB exposure levels in the summer. 118 Yet another study examined the association of VDR genotypes (variants at the CDX-2, Fok1 and Taq1 sites), haplotypes and genotype combinations with prostate cancer risk by studying 368 prostate cancer and 243 benign BPH patients. It found that CDX-2, Fok1 and Taq1 genotype and haplotype frequencies were not significantly different in cancer and BPH patients. It also studied the associations of variants with risk in men stratified into low (below median) and high (above median) cumulative exposure/year groups. In men with UVB exposure above the median (1100 h per year), CDX-2 GA and AA (OR ¼ 2.11 and 2.02, respectively) and Fok1 ff (OR ¼ 2.91) were associated with increased prostate cancer risk. No associations were observed for Taq1 genotypes. These data indicated that VDR variants influence prostate cancer risk and that this association is dependent on the extent of UVB exposure. 119 Given the extensiveness of the available literature on the beneficial effect of sunlight exposure on prostate cancer risk, Moon et al. 120 conducted a review study and concluded that exposure to UVB lowers the risk of prostate cancer. Their findings suggest that, first, host factors, such as skin pigmentation, that affect UVBinduced synthesis of vitamin D and, second, polymorphism in genes that mediate the effectiveness of vitamin D action affect the risk for a variety of diseases including prostate cancer. Similarly, Bodiwala et al. 121 conducted a study to confirm this hypothesis in 212 prostate adenocarcinoma and 135 BPH patients. Their aim was to determine whether earlier findings showing a protective effect for UVB exposure could be reproduced. They confirmed that higher levels of cumulative exposure, adult sunbathing, childhood sunburning and regular holidays in hot climates were each independently and significantly associated with a reduced risk of prostate cancer. Another study was conducted to determine whether VDR (Taql and Fokl variants), tyrosinase (TYR, codon 192 variant) and melanocortin-1 receptor (MC1R, Arg151Cys, Arg160Trp, Val92Met, Asp294His and Asp84Glu variants) genotypes were associated with prostate cancer risk. UVB exposure was determined using a questionnaire. Stratification of cases and controls by quartiles of exposure showed that the protective effect of TYR A1A2 (P ¼ 0.006, OR ¼ 0.075) and A2A2 (P ¼ 0.003, OR ¼ 0.055) was particularly strong in subjects who had received the greatest exposure. They showed that allelism in genes linked with skin pigment synthesis is associated with prostate cancer risk possibly because it mediates the protective effects of UVB. Hence, they concluded that susceptibility to prostate cancer is associated with an interaction between host predisposition and sun exposure. 122 
Discussion
Carcinoma of the prostate continues to be a major health problem in the United States. Newly diagnosed prostate 99 of a 40% risk reduction with 4600 IU of supplemental vitamin D intake compared with men not using supplements may suggest that dietary intake of vitamin D needs to be higher than the current dietary reference intake to be protective. The current dietary reference intakes are set based on the assumption that some of our need for vitamin D can be met with sun/UVB exposure. As individuals are spending less time in the sun and/or wearing sunscreen, there is current speculation that the dietary reference intakes may need to be increased. If this happens, intake from a combination of food and supplements may have to exceed 600 IU. Finally, we also reviewed seven studies evaluating serum levels of 25(OH)D and prostate cancer risk. These studies yielded conflicting results, with four studies showing no correlation with serum levels and prostate cancer risk. One study showed increased risk with both low and high serum levels. 106 One study by Ahonen et al. 78 found that low serum levels were associated with increased risk of prostate cancer. Future studies in this area should address timing of the drawing of serum levels and development of disease, as well as considering serial measurements of vitamin D over time. For example, the study by Nomura et al. 103 relied on a one-time blood draw and correlated that draw with the development of disease after a 23-year surveillance period. It is likely that there were fluctuations in serum levels over that time period.
Attempts to review this literature were conducted before this one. The first one was conducted in 1999. The paper gave in-depth information about the in vitro and in vivo studies but did not describe the epidemiological studies in detail. 40 A second review conducted recently concluded that the evidence to date does not strongly support an association between plasma vitamin D status in adulthood and prostate cancer risk. However, the authors cautioned that the absence of a link between vitamin D and prostate cancer risk, even if ultimately confirmed, should not be misinterpreted as evidence against other well-documented health benefits of vitamin D. The review did not describe all available epidemiological studies in the literature on the association between vitamin D and prostate cancer risk. 123 To further confirm the potential protective effects of calcium and vitamin D on prostate cancer, well-designed cohort studies and clinical trials are warranted. A few clinical trials have been conducted to study this hypothesis. In a secondary analysis of a clinical trial designed to investigate calcium supplementation as a chemopreventive strategy against colorectal cancer, Baron et al. We conclude that even though the results of epidemiological studies are conflicting, we should not ignore the fact that vitamin D deficiency is found to be associated with prostate cancer risk either as primarily as UVB exposure, or as a dietary factor, or as an endogenous entity. A thorough research on this subject in the form of large prospective observational studies and interventional clinical trials in the near future will provide us with a better understanding of the role of vitamin D in preventing prostate cancer.
